AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19657112 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant allele of SHBG SNP rs6259
Number of subjects: 529
Study 19657112 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant allele of SHBG SNP rs6257
Number of subjects: 529
Study 19657112 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in plasma level of sex hormone-binding globulin (SHBG)
Number of subjects: 529
Study 16920503 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative recombinant human GM-CSF (rhGM-CSF) administration
Number of subjects: 0
Study 16920503 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15309484 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with verteporfin
Number of subjects: 30
Study 15309484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11383355 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 implants with ball attachment
Number of subjects: 110
Study 11383355 — intervention group
Group type: COMPARATOR
Intervention: 2 implants interconnected with a bar
Number of subjects: 110
Study 11383355 — intervention group
Group type: COMPARATOR
Intervention: 4 implants interconnected with bars
Number of subjects: 110
Study 8996264 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/epinephrine injectable gel (5-FU/epi gel)
Number of subjects: 122
Study 8996264 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/epinephrine injectable gel (5-FU/epi gel) at a dose of 0.5 ml three times a week for 2 weeks
Number of subjects: 122
Study 7986856 — intervention group
Group type: COMPARATOR
Intervention: Group I (without lipid): received 100% of caloric intake (CI) by glucose
Number of subjects: 21
Study 7986856 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (LCT): received 55% of CI by glucose and 45% by LCT at 20% emulsion
Number of subjects: 21
Study 7986856 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (MCT/LCT): received 55% of CI by glucose and 45% by MCT/LCT at 20% mixture
Number of subjects: 21
Study 3257376 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 34
Study 30477846 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-specific suggestions (using counter-hyperarousal hypnotic exercise and screen visualization technique)
Number of subjects: 60
Study 30477846 — intervention group
Group type: COMPARATOR
Intervention: Generic suggestions (using thought distraction technique and suggestions for self-confidence and self-care enhancement)
Number of subjects: 60
Study 30477846 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 28556577 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise at 70% VO2 max
Number of subjects: 30
Study 28556577 — intervention group
Group type: COMPARATOR
Intervention: Control condition at 20% VO2 max
Number of subjects: 30
Study 25909533 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-connected partial dentures
Number of subjects: 20
Study 25909533 — intervention group
Group type: COMPARATOR
Intervention: Tooth-connected partial dentures
Number of subjects: 20
Study 23934169 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (HES)
Number of subjects: 55
Study 23934169 — intervention group
Group type: COMPARATOR
Intervention: 5% human serum albumin (HSA)
Number of subjects: 55
Study 16622463 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy (DD) with epirubicin 90 mg/m² plus paclitaxel 175 mg/m² in four 14-day cycles, followed by CMF 600/40/600 in three 14-day cycles, plus filgrastim 5 µg/kg/day
Number of subjects: 216
Study 16622463 — intervention group
Group type: COMPARATOR
Intervention: Conventional-schedule chemotherapy (CS) with epirubicin 90 mg/m² plus cyclophosphamide 600 mg/m² in four 21-day cycles, followed by CMF 600/40/600 in three 21-day cycles, plus filgrastim if required
Number of subjects: 216
Study 14527816 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral X-ray computed tomography
Number of subjects: 18
Study 14527816 — intervention group
Group type: EXPERIMENTAL
Intervention: Registration technique to align spiral X-ray computed tomography data with pressure sensor data
Number of subjects: 18
Study 10195613 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine administered 1-6 days after measles vaccination
Number of subjects: 294
Study 10195613 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine administered 7-13 days after measles vaccination
Number of subjects: 294
Study 10195613 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine administered 14-21 days after measles vaccination
Number of subjects: 294
Study 10195613 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine administered 22-27 days after measles vaccination
Number of subjects: 294
Study 10195613 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine administered >28 days after measles vaccination
Number of subjects: 294
Study 8538116 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 degrees C (tepid)
Number of subjects: 100
Study 8538116 — intervention group
Group type: COMPARATOR
Intervention: 28 degrees C
Number of subjects: 100
Study 8538116 — intervention group
Group type: COMPARATOR
Intervention: 30 degrees C
Number of subjects: 100
Study 8538116 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study 1962905 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (FR‐860)
Number of subjects: 10
Study 1962905 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (H‐25)
Number of subjects: 10
Study 1962905 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (F‐50)
Number of subjects: 10
Study 1962905 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (F‐25 and F‐35)
Number of subjects: 10
Study 1962905 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 10
Study 1962905 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 10
Study 6101748 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase, carcinoembryonic antigen, and gamma‐glutamyl transpeptidase tests
Number of subjects: 47
Study 6101748 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination, chest X‐ray, and the three tumour markers
Number of subjects: 47
Study 31884898 — intervention group
Group type: EXPERIMENTAL
Intervention: Jigsaw method
Number of subjects: 0
Study 31884898 — intervention group
Group type: COMPARATOR
Intervention: Traditional small group method
Number of subjects: 0
Study 29625777 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary Rehabilitation (PR) thrice weekly for 12 weeks
Number of subjects: 120
Study 29625777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi five times weekly for 12 weeks
Number of subjects: 120
Study 28598826 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 186
Study 28598826 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Vitamin E)
Number of subjects: 186
Study 28598826 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 186
Study 26302142 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month pharmacist intervention comprising collaborative care, medication review, and tailored adherence counseling including motivational interviewing and telephone follow-ups.
Number of subjects: 532
Study 26302142 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 532
Study 26302142 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month pharmacist intervention.
Number of subjects: 532
Study 23208945 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification-based cognitive functional therapy
Number of subjects: 121
Study 23208945 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy and exercise
Number of subjects: 121
Study 21406499 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 34
Study 21406499 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular corticosteroid injections
Number of subjects: 34
Study 18192510 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose senicapoc (10 mg/day)
Number of subjects: 0
Study 18192510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15708225 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifid VEP in patients with demyelinating disease (90 patients)
Number of subjects: 116
Study 15708225 — intervention group
Group type: COMPARATOR
Intervention: Bifid VEP in healthy controls (50 persons)
Number of subjects: 116
Study 15708225 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifid VEP in patients with unconfirmed suspicion for MS (26 patients)
Number of subjects: 116
Study 14529061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra®)
Number of subjects: 120
Study 14529061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 14529061 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label studies
Number of subjects: 120
Study 10568568 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric-oxide-generating gel
Number of subjects: 30
Study 10568568 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (KY jelly only)
Number of subjects: 30
Study 8947701 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized computer-based information
Number of subjects: 0
Study 8947701 — intervention group
Group type: COMPARATOR
Intervention: General computer-based information
Number of subjects: 0
Study 1751080 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69S membrane dialyzers
Number of subjects: 49
Study 1751080 — intervention group
Group type: COMPARATOR
Intervention: Cellulosic dialyzers
Number of subjects: 49
Study 7061569 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 7061569 — intervention group
Group type: COMPARATOR
Intervention: Normal adult volunteers
Number of subjects: 0
Study 7061569 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bad performance status
Number of subjects: 0
Study 7061569 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stage III primary lung cancer
Number of subjects: 0
Study 7061569 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients after chemotherapy
Number of subjects: 0
Study 30835326 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-speed rotational atherectomy (RA) at 135,000 rpm with substantial debulking before stenting
Number of subjects: 889
Study 30835326 — intervention group
Group type: COMPARATOR
Intervention: Non-RA treatment
Number of subjects: 889
Study 29089056 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotilaner (20-43 mg/kg)
Number of subjects: 28
Study 29089056 — intervention group
Group type: COMPARATOR
Intervention: Sham-treated control
Number of subjects: 28
Study 26227783 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg synthetic GABA
Number of subjects: 30
Study 26227783 — intervention group
Group type: COMPARATOR
Intervention: 800 mg oral microcrystalline cellulose (placebo)
Number of subjects: 30
Study 23038750 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill strategy (combining aspirin, a statin, and two blood pressure lowering agents)
Number of subjects: 2000
Study 23038750 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2000
Study 23342824 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 23
Study 23342824 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 23
Study 20137476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone (10 mg/kg daily for 7 days before surgery and 200 mg daily for 10 days postoperatively)
Number of subjects: 210
Study 20137476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 20137476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone
Number of subjects: 210
Study 17448696 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic distal clavicle excision
Number of subjects: 17
Study 17448696 — intervention group
Group type: COMPARATOR
Intervention: Open distal clavicle excision
Number of subjects: 17
Study 15219661 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone
Number of subjects: 22
Study 15219661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11575001 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble thrombomodulin concentration in lung cancer patients
Number of subjects: 33
Study 11575001 — intervention group
Group type: COMPARATOR
Intervention: Control group (adults)
Number of subjects: 33
Study 11575001 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between stages IB and IIIB
Number of subjects: 33
Study 9833596 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic propafenone (150 mg every 6 h)
Number of subjects: 8
Study 9833596 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)‐propafenone (150 mg every 6 h)
Number of subjects: 8
Study 9833596 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)‐propafenone (150 mg every 6 h)
Number of subjects: 8
Study 9833596 — intervention group
Group type: COMPARATOR
Intervention: Racemic propafenone, (S)‐propafenone, (R)‐propafenone
Number of subjects: 8
Study 9833596 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic propafenone, (S)‐propafenone
Number of subjects: 8
Study 9833596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8589464 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 79
Study 8589464 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight dextran
Number of subjects: 79
Study 8589464 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 79
Study 8589464 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient age, use of calcium channel blockers, presence of diabetes mellitus (DM)
Number of subjects: 79
Study 8589464 — intervention group
Group type: EXPERIMENTAL
Intervention: Time on dialysis pre graft placement
Number of subjects: 79
Study 2666363 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant CMF chemotherapy
Number of subjects: 0
Study 2666363 — intervention group
Group type: COMPARATOR
Intervention: Initial local control with radiation therapy or radiation plus surgery
Number of subjects: 0
Study 2666363 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage therapy for metastatic disease
Number of subjects: 0
Study 793437 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (HLI) 3 X 10(‐6) units/ml, two drops twice daily
Number of subjects: 40
Study 793437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30700356 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab with neoadjuvant chemotherapy (n=89, n=64 received complete standard dose)
Number of subjects: 156
Study 30700356 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy only (Control group, n=67)
Number of subjects: 156
Study 28493519 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 10
Study 28493519 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 10
Study 25758676 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill walking (DW)
Number of subjects: 10
Study 25758676 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill walking with load (DWL)
Number of subjects: 10
Study 25758676 — intervention group
Group type: COMPARATOR
Intervention: Level walking (LW)
Number of subjects: 10
Study 22898654 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education program (6 sessions à 90 min)
Number of subjects: 261
Study 22069954 — intervention group
Group type: EXPERIMENTAL
Intervention: Emospid
Number of subjects: 69
Study 22069954 — intervention group
Group type: COMPARATOR
Intervention: MMDH
Number of subjects: 69
Study 19176440 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal BNP-guided therapy
Number of subjects: 499
Study 19176440 — intervention group
Group type: COMPARATOR
Intervention: Symptom-guided therapy
Number of subjects: 499
Study 16573580 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 30
Study 16573580 — intervention group
Group type: COMPARATOR
Intervention: Acamprosate (ACP)
Number of subjects: 30
Study 16573580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OXC and ACP
Number of subjects: 30
Study 12754730 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpsychotic group nurses (read vignette with patient on alprazolam)
Number of subjects: 60
Study 12754730 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic group nurses (read vignette with patient on haloperidol, benztropine, lorazepam, trazadone, fluoxetine, and lithium)
Number of subjects: 60
Study 12754730 — intervention group
Group type: COMPARATOR
Intervention: Control group nurses (read vignette without psychiatric medication)
Number of subjects: 60
Study 11286449 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive anaesthesia
Number of subjects: 53
Study 11286449 — intervention group
Group type: COMPARATOR
Intervention: Normotensive anaesthesia
Number of subjects: 53
Study 9369825 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline sulfate (0.25 mg)
Number of subjects: 179
Study 9369825 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 179
Study 9369825 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydration
Number of subjects: 179
Study 1395634 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUE Test
Number of subjects: 413
Study 1395634 — intervention group
Group type: COMPARATOR
Intervention: Finn Chamber
Number of subjects: 413
Study 1395634 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TRUE Test and Finn Chamber
Number of subjects: 413
Study 1395634 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUE Test only
Number of subjects: 413
Study 1395634 — intervention group
Group type: EXPERIMENTAL
Intervention: Finn Chamber only
Number of subjects: 413
Study 1395634 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant positive reactions
Number of subjects: 413
Study 2859421 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP (mustine, vincristine, procarbazine, and prednisone)
Number of subjects: 0
Study 2859421 — intervention group
Group type: EXPERIMENTAL
Intervention: Local involved-field irradiation
Number of subjects: 0
Study 2859421 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic survival index (greater than 7.5)
Number of subjects: 0
Study 2859421 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, sex, erythrocyte sedimentation (ESR), presence or absence of mediastinal involvement, pathological grade
Number of subjects: 0
Study 2859421 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 0
Study 31383978 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary food with rapeseed oil (IG-R)
Number of subjects: 160
Study 31383978 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary food with oily fish (IG-F)
Number of subjects: 160
Study 31383978 — intervention group
Group type: COMPARATOR
Intervention: Control group with corn oil (CG)
Number of subjects: 160
Study 30113750 — intervention group
Group type: EXPERIMENTAL
Intervention: VIB (40 Hz)
Number of subjects: 10
Study 30113750 — intervention group
Group type: COMPARATOR
Intervention: TRAD (traditional HIT session without vibration)
Number of subjects: 10
Study 27790772 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel contact lens
Number of subjects: 103
Study 27790772 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone hydrogel contact lens
Number of subjects: 103
Study 27790772 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic group
Number of subjects: 103
Study 27790772 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic group
Number of subjects: 103
Study 24773760 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MIG) plus standard care (information sheet on glaucoma and its treatment)
Number of subjects: 300
Study 24773760 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 300
Study 22466942 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular therapy combined with optimized Yinxieling Formula
Number of subjects: 84
Study 22466942 — intervention group
Group type: COMPARATOR
Intervention: Optimized Yinxieling Formula alone
Number of subjects: 84
Study 22466942 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 20184810 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized social phobia (GSP) patients
Number of subjects: 48
Study 20184810 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study 18517091 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood-based physical activity intervention
Number of subjects: 573
Study 15951736 — intervention group
Group type: EXPERIMENTAL
Intervention: PTNS performed weekly (Group A)
Number of subjects: 35
Study 15951736 — intervention group
Group type: EXPERIMENTAL
Intervention: PTNS performed 3 times per week (Group B)
Number of subjects: 35
Study 11871949 — intervention group
Group type: EXPERIMENTAL
Intervention: intubating laryngeal mask‐blind group
Number of subjects: 60
Study 11871949 — intervention group
Group type: EXPERIMENTAL
Intervention: intubating laryngeal mask‐fibreoptic group
Number of subjects: 60
Study 11871949 — intervention group
Group type: EXPERIMENTAL
Intervention: laryngeal mask‐fibreoptic group
Number of subjects: 60
Study 10600247 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (single dose)
Number of subjects: 0
Study 10600247 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched drink)
Number of subjects: 0
Study 7605835 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (monophasic pulse, small anode, large cathode, frequency 20 Hz) for 20 min
Number of subjects: 50
Study 7605835 — intervention group
Group type: COMPARATOR
Intervention: Conventional TENS (biphasic pulse, electrodes of identical size, frequency 100 Hz) for 20 min
Number of subjects: 50
Study 2220647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic therapy combined with one of five active drug regimens (acebutolol, amlodipine, chlorthalidone, doxazosin, enalapril)
Number of subjects: 0